Tom Bradley offers a lesson in improving hiring processes. As formerly rock-solid revenue streams dry up, many life sciences companies are paying closer than ever scrutiny to operating costs. With people costs...
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.